April 15, 2019 / 5:14 AM / 2 months ago

BRIEF-Genfit Presents Additional Data from Positive Phase 2 Clinical Trial Of Elafibranor

April 15 (Reuters) - GENFIT SA:

* SAID ON SATURDAY FURTHER ANALYSIS SHOWS SIGNIFICANT IMPROVEMENTS IN PBC CHOLESTATIC MARKERS AND REDUCTION ON IMMUNO/INFLAMMATION MARKERS

* SIGNIFICANT DECREASE IN BILE ACID PRECURSORS AND IMPROVEMENT IN METABOLIC MARKERS

* NEW DATA ALSO SUGGEST IMPROVEMENT IN PRURITUS

* NEW DATASET FURTHER SUPPORTS ELAFIBRANOR’S POTENTIAL FOR IMPROVED EFFICACY AND TOLERABILITY COMPARED TO EXISTING PBC THERAPIES

Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below